Mirati Therapeutics Profit Margin

The latest profit margin for MRTX is -1876.47% as of September 2023. That compares with -6253.81% in the prior-year period — up 70.0% year over year. That is below the Healthcare sector average of 14.41%. Investors often review this figure alongside Mirati Therapeutics's historical trend and sector peers before judging valuation or financial health.

Over the past year, MRTX's profit margin moved from -6253.81% to -1876.47% — a 70.0% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Mirati Therapeutics's valuation or profitability profile.

Against Healthcare companies, MRTX currently prints -1876.47% for profit margin, while the sector average sits near 14.41%. That is roughly 13117.6% below the sector mean. Large gaps often invite a closer look at Mirati Therapeutics's growth, margins, and balance sheet.

Profit Margin shows how effectively Mirati Therapeutics converts resources into returns. At -1876.47%, MRTX may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -6253.81% in the prior-year period — up 70.0% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting MRTX's profit margin (-1876.47%), review year-over-year change from -6253.81%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.